ISI provided color on Bristol Myers Squibb BMY. In a research report published today, ISI commented on the likelihood FDA will not approve the company's new drug.
In the report, ISI states, “We are lowering our probability of success for dapa from 55% to 20% to reflect the 9 to 6 negative vote at today's FDA AdCom (FDA felt that safety issues such as liver toxicity & cancer imbalances needed further study/analysis). We would note there is a chance that FDA still approves the drug (after a likely delay of 6-12 months) with stringent warnings and/or a REMS program.“
On Tuesday, BMY added 0.52% to its value to finish the day at $28.81. Its shares lost some of yesterday's gains in today's pre-market trading, sliding 0.07% to $28.79.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in